Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma
- 1 July 1997
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (8) , 1326-1329
- https://doi.org/10.1016/s0959-8049(97)00120-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanomaBritish Journal of Cancer, 1993
- Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cellsBritish Journal of Cancer, 1993
- Fotemustine plus dacarbazine for malignant melanomaEuropean Journal Of Cancer, 1992
- Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma—an effective combination with unexpected toxicityEuropean Journal Of Cancer, 1992
- Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.Journal of Clinical Oncology, 1991
- Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesCancer, 1990
- Phase II Study of Interferon α-2a and Dacarbazine in Advanced MelanomaAmerican Journal of Clinical Oncology, 1990
- Interferon α-2a and Dacarbazine in MelanomaJNCI Journal of the National Cancer Institute, 1990
- A generalized two-sample Wilcoxon test for doubly censored dataBiometrika, 1965
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958